| Li, Yang |
NCT05433480: A Study of BPI-16350 in Combination With Fulvestrant in Patients With HR+ and HER2- Locally Advanced, Recurrent or Metastatic Breast Cancer |
|
|
| Active, not recruiting | 3 | 274 | RoW | BPI-16350, placebo, Fulvestrant | Betta Pharmaceuticals Co., Ltd. | Breast Cancer | 12/23 | 07/25 | | |
NCT06419621: PM8002 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/Metastatic Triple-negative Breast Cancer |
|
|
| Recruiting | 3 | 360 | RoW | PM8002, Nab-Paclitaxel, Placebo | Biotheus Inc. | Triple Negative Breast Cancer(TNBC) | 07/27 | 07/28 | | |
BEconneCTD-ILD, NCT06572384: A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease |
|
|
| Recruiting | 3 | 440 | Europe, Japan, US, RoW | Belimumab, BENLYSTA, GSK1550188, Placebo | GlaxoSmithKline | Lung Diseases, Interstitial | 10/28 | 12/28 | | |
| Recruiting | 3 | 1200 | Europe, Canada, Japan, US, RoW | Remternetug, LY3372993, Placebo | Eli Lilly and Company | Alzheimer's Disease | 04/29 | 10/30 | | |
NCT05737303: Nab-paclitaxel Versus Sb-taxanes As First-Line Treatment in Advanced Ovarian Cancer |
|
|
| Recruiting | 3 | 538 | RoW | nab-paclitaxel combined with carboplatin, paclitaxel combined with carboplatin | Women's Hospital School Of Medicine Zhejiang University, Jiaxing Maternity and Child Health Care Hospital, Zhejiang University, Second Affiliated Hospital, School of Medicine, Zhejiang University, First Affiliated Hospital of Wenzhou Medical University, Second Affiliated Hospital of Wenzhou Medical University, Sun Yat-sen University, Qilu Hospital of Shandong University, Ningbo No. 1 Hospital, Ningbo Women & Children's Hospital, Sir Run Run Shaw Hospital | Epithelial Ovarian Carcinoma Stage III, Epithelial Ovarian Carcinoma Stage IV, Fallopian Tube Carcinoma Stage III, Fallopian Tube Carcinoma Stage IV, Primary Peritoneal Carcinoma Stage III, Primary Peritoneal Carcinoma Stage IV | 12/24 | 12/27 | | |
| Recruiting | 3 | 1500 | Europe, RoW | Donanemab, (LY3002813), Placebo | Eli Lilly and Company | Alzheimer Disease, Dementia, Brain Diseases, Central Nervous System Diseases, Nervous System Diseases, Tauopathies, Neurodegenerative Diseases, Neurocognitive Disorders, Mental Disorders | 04/27 | 04/27 | | |
| Recruiting | 2/3 | 240 | Europe, Canada, Japan, US, RoW | EFG PH20 SC, PBO | argenx, argenx BV | Active Idiopathic Inflammatory Myopathy, Myositis, Dermatomyositis, Polymyositis, Immune-Mediated Necrotizing Myopathy, Antisynthetase Syndrome | 12/26 | 02/27 | | |
NCT05407246: Phase II Study of Hemay005 in Patients With Active Ankylosing Spondylitis |
|
|
| Completed | 2 | 90 | RoW | Hemay005, placebo | Tianjin Hemay Pharmaceutical Co., Ltd | Active Ankylosing Spondylitis | 08/23 | 08/23 | | |
NCT06250062: A Clinical Study of JS005 in Patients With Ankylosing Spondylitis |
|
|
| Recruiting | 2 | 261 | RoW | Recombinant humanized IL-17A Monoclonal Antibody（JS005）, Placebo（JS005） | Shanghai Junshi Bioscience Co., Ltd., Sponsor GmbH | Ankylosing Spondylitis | 02/25 | 10/25 | | |
NCT05269173: Efficacy and Safety of Flos Gossypii Flavonoids Tablet in the Treatment of Alzheimer's Disease |
|
|
| Completed | 2 | 240 | RoW | Flos gossypii flavonoids tablet | Capital Medical University, Xinjiang Uygur Pharmaceutical Co., Ltd. | Alzheimer Disease | 08/24 | 11/24 | | |
NCT05896124: CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis) |
|
|
| Recruiting | 2 | 75 | RoW | 2mg CS0159, Placebo | Cascade Pharmaceuticals, Inc | Primary Biliary Cholangitis (PBC) | 10/24 | 10/24 | | |
NCT05998759: Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia |
|
|
| Recruiting | 2 | 296 | RoW | Telitacicept, recombinant human B lymphocyte stimulating factor receptor-Fc fusion protein, Recombinant Human B Lymphocyte(RC18), Tai'ai®, Placebo, Placebo control, control | Beijing Hospital, The First Affiliated Hospital of Anhui Medical University, The First Affiliated Hospital of China University of Science and Technology (Anhui Provincial), Peking University People's Hospital, Peking University Third Hospital, First Affiliated Hospital, Sun Yat-Sen University, Guangdong Provincial People's Hospital, The First Affiliated Hospital of Zhengzhou University, Wuhan Union Hospital, China, Second Xiangya Hospital of Central South University, Xiangya Hospital of Central South University, The Affiliated Hospital of Inner Mongolia Medical University, First Hospital of China Medical University, Shandong Provincial Hospital, Changhai Hospital, RenJi Hospital, Shanxi Bethune Hospital, West China Hospital, Institute of Hematology & Blood Diseases Hospital, China, Tianjin First Central Hospital, Tianjin Medical University General Hospital, People's Hospital of Xinjiang Uygur Autonomous Region, The First People's Hospital of Yunnan | Connective Tissue Diseases, Thrombocytopenia | 12/25 | 12/25 | | |
NCT05303727: Allogeneic Hematopoietic Stem Cell Transplantation for 4/M Neuroblastoma |
|
|
| Not yet recruiting | 2 | 64 | RoW | Anti Thymocyte Globulin, ATG, Fludarabine, Fludara, Cyclophosphamide injection, CTX, Topotecan, Topotecan Hydrochloride, Melphalan, Alkeran, Thiotepa, thiophosphoramide, Busulfan, Busulfex, Cyclosporine, Sandimmune, Tacrolimus, Prograf, Mycophenolate Mofetil, Cellcept, Methotrexate, amethopterin | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Neuroblastoma | 08/27 | 08/27 | | |
NCT03503864: Phase II Study of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M Neuroblastoma |
|
|
| Recruiting | 2 | 65 | RoW | Arsenic Trioxide, ATO | Yang Li | Neuroblastoma | 12/28 | 12/28 | | |
NCT06088030: Arsenic Trioxide Combined With Chemotherapy for the Treatment of p53-mutated Pediatric Cancer |
|
|
| Recruiting | 2 | 50 | RoW | Arsenic trioxide, ATO | Yang Li, Ruijin Hospital | Pediatric Cancer, Li-Fraumeni Syndrome, p53 Mutations | 12/31 | 12/31 | | |
NCT06339021: OCT or Angiography Guided De-escalation of DAPT |
|
|
| Not yet recruiting | 1 | 80 | RoW | OCT-guided PCI, Conventional angiography-based PCI, DAPT de-escalation, default DAPT regimen | Shenyang Northern Hospital | Optical Coherence Tomography, Dual Antiplatelet Therapy, Antiplatelet De-escalation, Neointimal Coverage, ST Elevation Myocardial Infarction | 12/26 | 12/26 | | |
NCT06190457: Safety and Efficacy of Intrathecal Rituximab in 16 Children of Stage Ⅲ、ⅣNon-Hodgkin Lymphoma |
|
|
| Completed | N/A | 16 | NA | intrathecal rituximab | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Lymphoma, Non-Hodgkin, Child, Only | 12/20 | 08/22 | | |
NCT05860491: Dietary Fiber and Hyperkalemia in Dialysis Patients |
|
|
| Completed | N/A | 100 | RoW | dietary fiber | Qianfoshan Hospital | Hyperkalemia, Hemolysis | 06/22 | 06/22 | | |
NCT05011552: Feasibility Study for Abused Chinese Immigrant Women |
|
|
| Completed | N/A | 50 | US | Self-Compassion, Health, and Empowerment (SHE), The Control Condition | University of Texas at Austin | Intimate Partner Violence, Depression, Anxiety, PTSD | 03/23 | 03/23 | | |
NCT06417736: Prospective Study for Endometrial Carcinoma and Hyperplasia in Childbearing-age Women |
|
|
| Recruiting | N/A | 75 | RoW | Megestrol Acetate 40 MG, membrane-inhibiting formula | Women's Hospital School Of Medicine Zhejiang University | Endometrial Cancer Stage I, Endometrial Hyperplasia | 07/25 | 12/26 | | |
| Recruiting | N/A | 590 | RoW | Vaginal brachytherapy, External beam radiotherapy, Observation, Chemoradiation therapy | Women's Hospital School Of Medicine Zhejiang University, Tongji Hospital, Qilu Hospital of Shandong University, Obstetrics & Gynecology Hospital of Fudan University, Sun Yat-sen University, Peking University People's Hospital, Shanghai First Maternity and Infant Hospital, Xiangya Hospital of Central South University, Anhui Provincial Cancer Hospital, Ningbo Women & Children's Hospital, Ningbo No. 1 Hospital | Endometrial Cancer Stage I, Endometrial Cancer Stage II | 12/24 | 01/27 | | |
NCT06459427: Robot-Assisted Minimally Invasive Surgery for Brainstem Hemorrhage |
|
|
| Not yet recruiting | N/A | 110 | RoW | Robot-Assisted Stereotactic Brainstem Hematoma Puncture, "Remebot" Neurosurgical Robot, Conservative non-surgical treatment, Medical therapy | Yanbing Yu | Brain Stem Hemorrhage, Robotic Surgical Procedures, Stereotactic Techniques | 12/27 | 12/27 | | |
INSPIRE-TB, NCT05081401: Innovating(IN) Shorter(S), All- Oral, Precised(P), Individualized(I) Treatment Regimen(RE) for Rifampicin Resistant Tuberculosis |
|
|
| Recruiting | N/A | 3000 | RoW | This is a non-intervention observational study. | Huashan Hospital | Multidrug Resistant Tuberculosis | 12/25 | 12/25 | | |
| Not yet recruiting | N/A | 500 | RoW | | Huashan Hospital | Multidrug Resistant Tuberculosis | 12/22 | 12/22 | | |
NCT05542784: Modified Laparoendoscopic Rendezvous for Secondary Choledocholithiasis: a Nonrandomized Controlled Clinical Study |
|
|
| Recruiting | N/A | 90 | RoW | Modified LERV, Pre ERCP+LC | Shenzhen Second People's Hospital | Choledocholithiasis | 03/25 | 07/25 | | |
| jun, li ai |
| Completed | N/A | 64 | RoW | SFEE Diet Management Intervention, Standard Dietary Advice | Ji Jing | Gestational Diabetes Mellitus (GDM) | 03/24 | 03/24 | | |
NCT05875584: Exploratory Study of a Novel Based rbcDNA Liquid Biopsy Technique for Colorectal Cancer Early Detection |
|
|
| Completed | N/A | 598 | RoW | rbcDNA test, FIT | Second Affiliated Hospital, School of Medicine, Zhejiang University, Timing Biotech Co.Ltd. | Colorectal Cancer, Adenomatous Polyps, Adenoma, Advanced Adenoma | 12/23 | 01/24 | | |
| Kang, Yan |
NCT02654561: Efficacy and Safety of Unfractionated Heparin on Severe Sepsis With Suspected Disseminated Intravascular Coagulation |
|
|
| Recruiting | 3 | 600 | RoW | Heparin Sodium, Unfractionated heparin, Saline, Normal saline | China Medical University, China, West China Hospital, Zhongda Hospital, The First Affiliated Hospital of Dalian Medical University, Shengjing Hospital, The First Hospital of Jilin University, Qilu Hospital of Shandong University, The Second Affiliated Hospital of Kunming Medical University, The First Hospital of Qinhuangdao, The Second Affiliated Hospital of Dalian Medical University, First Affiliated Hospital of Harbin Medical University, Peking University People's Hospital, The People's Hospital of Liaoning Province, Fourth People's Hospital of Shenyang, Beijing Tsinghua Changgeng Hospital, First Affiliated Hospital of Kunming Medical University, The Affiliated Hospital of Qingdao University, Beijing Friendship Hospital, General Hospital of Ningxia Medical University, The First Affiliated Hospital of Nanchang University | Sepsis, Disseminated Intravascular Coagulation | 12/24 | 06/25 | | |
NCT06351150: Efficacy and Safety of Angiotensin II Injection Versus Placebo in Patients With Refractory Distributed Shock |
|
|
| Not yet recruiting | 3 | 214 | RoW | Angiotensin II Injection, 0.9% sodium chloride injection | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Vasodilatory Shock | 06/27 | 12/27 | | |
NCT03549910: A Multicenter, Random Control Study :Early Use of Airway Pressure Release Ventilation (APRVplus) Protocol in ARDS |
|
|
| Recruiting | N/A | 840 | RoW | APRVplus protocol, Low tidal volume ventilation | West China Hospital | Acute Respiratory Distress Syndrome | 12/24 | 12/24 | | |
NCT06574659: Noninvasive Ventilation Breathing Test Guiding Weaning in Patients With Acute Hypoxic Respiratory Failure |
|
|
| Recruiting | N/A | 150 | RoW | Noninvasive ventilation breathing test guiding sequential invasive Ventilation and noninvasive ventilation weaing protocol, The standard SBT guiding weaning group | West China Hospital, Sichuan University, Dazhou Central Hospital | Acute Hypoxic Respiratory Failure | 12/24 | 12/24 | | |
| Huo, Lijuan |
NCT05181137 / 2021-001940-86: A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis |
|
|
| Recruiting | 3 | 368 | Europe, US, RoW | SHR0302, Placebo | Reistone Biopharma Company Limited, Reistone Biopharma Company Limited | Ulcerative Colitis | 10/24 | 03/25 | | |
| Zhang, Liaoyun |
NCT05182463: Peginterferon Treatment Study for Inactive Chronic Hepatitis B Patients |
|
|
| Recruiting | 4 | 5000 | RoW | Peginterferon Alfa-2B, Nucleoside Analogs | Third Affiliated Hospital, Sun Yat-Sen University | Hepatitis B, Chronic | 12/26 | 11/29 | | |
| Active, not recruiting | 3 | 871 | Europe, Canada, Japan, US, RoW | Bepirovirsen, Placebo | GlaxoSmithKline, GlaxoSmithKline Research & Development Limited | Chronic Hepatitis B, Hepatitis B, Chronic | 11/25 | 05/26 | | |
NCT03108794: A Nation-wide Hospital-based Hepatitis B Registry:China Registry of Hepatitis B |
|
|
| Recruiting | N/A | 200000 | RoW | | Beijing Friendship Hospital, Beijing YouAn Hospital, The First Hospital of Jilin University, Henan Provincial People's Hospital, Beijing Ditan Hospital, First Affiliated Hospital of Xinjiang Medical University, LanZhou University, The Second Affiliated Hospital of Chongqing Medical University, West China Hospital, Taiyuan No.3 Hospital, Hebei Medical University Third Hospital, Shengjing Hospital, Tianjin Third Central Hospital, Peking University First Hospital, Peking Union Medical College Hospital, The Affiliated Hospital Of Southwest Medical University, Shanghai Public Health Clinical Center, Ruijin Hospital, First Affiliated Hospital Xi'an Jiaotong University, Xiangya Hospital of Central South University, Beijing Tiantan Hospital, Wuhan University, The First Affiliated Hospital of Kunming Medical College, The Affiliated Hospital of Xuzhou Medical University, The Affiliated Hospital of Yanbian University, First Affiliated Hospital of Chongqing Medical University, The Fouth Hospital of Qinghai province, Weifang Medical University, Hunan Provincial People's Hospital, The Second Hospital of Hebei Medical University, Xixi Hospital of Hangzhou, General Hospital of Ningxia Medical University, Union Hospital,Tong Ji Medical College,Huazhong University of Science and Technology, Xinjiang Uygur Autonomous Region Traditional Chinese Medicine Hospital, Peking University People's Hospital, Nanfang Hospital of Southern Medical University, The Affiliated Hospital Of Guizhou Medical University, Guizhou Provincial People's Hospital, Hainan General Hospital, The Second Hospital of Shandong University, The First Affiliated Hospital of Shanxi Medical University, Fifth Hospital of Shijiazhuang City, Yan'an University Affiliated Hospital, Infectious Disease Hospital of Wuhai, Logistics University of Chinese People's Armed Police Forces, People's Hospital of Changji Hui Autonomous Prefecture，Xinjiang | Chronic Hepatitis B | 12/22 | 12/25 | | |
NCT05965128: Promotion and Application of a New Three-level Etiological Diagnosis Strategy for Fever Clinics in Respiratory Infectious Diseases |
|
|
| Recruiting | N/A | 1255 | RoW | | Huashan Hospital | Respiratory Infectious Diseases | 12/23 | 12/27 | | |
NCT05855395: The Standard of Care Combined With Glucocorticoid in Elderly People With Mild or Moderate COVID-19 |
|
|
| Recruiting | N/A | 5815 | RoW | Glucocorticoid, dexamethasone, prednisone, methylprednisolone | Huashan Hospital | COVID-19 | 05/24 | 12/24 | | |
NCT06123858: Non-alcoholic Steatohepatitis Registry Platform Study |
|
|
| Recruiting | N/A | 2500 | RoW | | AstraZeneca | NASH With Fibrosis | 12/26 | 12/26 | | |
NCT05937178: Real-world Study Optimizing Nucleotide-analogues |
|
|
| Recruiting | N/A | 20000 | RoW | ETV/TAF/TDF/TMF/IFN, ETV/TAF/TDF/TMF | Huashan Hospital, The First Affiliated Hospital of Anhui Medical University, Anhui Provincial Hospital, Beijing YouAn Hospital, Peking University People's Hospital, Peking University First Hospital, Xiamen Hospital of Traditional Chinese Medicine, First Affiliated Hospital of Fujian Medical University, LanZhou University, Third Affiliated Hospital, Sun Yat-Sen University, First Affiliated Hospital of Guangxi Medical University, The Affiliated Hospital Of Guizhou Medical University, Hainan General Hospital, Hebei Medical University Third Hospital, The First Affiliated Hospital of Henan University of Traditional Chinese Medicine, Henan Provincial People's Hospital, The Second Affiliated Hospital of Harbin Medical University, Tongji Hospital, Wuhan Union Hospital, China, Renmin Hospital of Wuhan University, Central South University, Xiangya Hospital of Central South University, The First Hospital of Jilin University, the Second Hospital of Nangjing, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, The First Affiliated Hospital with Nanjing Medical University, The Affiliated Hospital of Xuzhou Medical University, The First Affiliated Hospital of Nanchang University, Shengjing Hospital, Qingdao Sixth People's Hospital, Shandong Provincial Hospital Affiliated to Shandong First Medical University, The Second Hospital of Shandong University, The First Affiliated Hospital of Shanxi Medical University, Tang-Du Hospital, First Affiliated Hospital Xi'an Jiaotong University, Ruijin Hospital, West China Hospital, Tianjin Second People's Hospital, First Affiliated Hospital of Xinjiang Medical University, The First People's Hospital of Yunnan, Shulan (Hangzhou) Hospital, Zhejiang University, Southwest Hospital, China, The Second Affiliated Hospital of Chongqing Medical University, Sichuan Provincial People's Hospital | Hepatitis B, Chronic | 01/29 | 01/29 | | |
NCT05086536: Re-compensation and Its Clinical Characteristics in HBV Decompensated Cirrhosis |
|
|
| Not yet recruiting | N/A | 600 | RoW | no intervention | Beijing Friendship Hospital, Beijing YouAn Hospital, Shandong Provincial Hospital, The Affiliated Hospital of Qingdao University, The First Affiliated Hospital of Shanxi Medical University, Xiangya Hospital of Central South University, The Second Affiliated Hospital of Baotou Medical College | Hepatitis B, Decompensated Cirrhosis | 06/22 | 12/22 | | |
| Zhang, Liyun |
NCT04830644: A Study to Evaluate the Efficacy and Safety of Iguratimod Compared to Placebo in Patients With Active Primary Sjogren's Syndrome. |
|
|
| Recruiting | 2 | 144 | RoW | Iguratimod, Placebo | Jiangsu Simcere Pharmaceutical Co., Ltd. | Primary Sjögren Syndrome | 04/22 | 06/22 | | |
NCT05269173: Efficacy and Safety of Flos Gossypii Flavonoids Tablet in the Treatment of Alzheimer's Disease |
|
|
| Completed | 2 | 240 | RoW | Flos gossypii flavonoids tablet | Capital Medical University, Xinjiang Uygur Pharmaceutical Co., Ltd. | Alzheimer Disease | 08/24 | 11/24 | | |
NCT05998759: Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia |
|
|
| Recruiting | 2 | 296 | RoW | Telitacicept, recombinant human B lymphocyte stimulating factor receptor-Fc fusion protein, Recombinant Human B Lymphocyte(RC18), Tai'ai®, Placebo, Placebo control, control | Beijing Hospital, The First Affiliated Hospital of Anhui Medical University, The First Affiliated Hospital of China University of Science and Technology (Anhui Provincial), Peking University People's Hospital, Peking University Third Hospital, First Affiliated Hospital, Sun Yat-Sen University, Guangdong Provincial People's Hospital, The First Affiliated Hospital of Zhengzhou University, Wuhan Union Hospital, China, Second Xiangya Hospital of Central South University, Xiangya Hospital of Central South University, The Affiliated Hospital of Inner Mongolia Medical University, First Hospital of China Medical University, Shandong Provincial Hospital, Changhai Hospital, RenJi Hospital, Shanxi Bethune Hospital, West China Hospital, Institute of Hematology & Blood Diseases Hospital, China, Tianjin First Central Hospital, Tianjin Medical University General Hospital, People's Hospital of Xinjiang Uygur Autonomous Region, The First People's Hospital of Yunnan | Connective Tissue Diseases, Thrombocytopenia | 12/25 | 12/25 | | |
NCT05247203: Telitacicept Study in Chinese Subjects With Systemic Lupus Erythematosus |
|
|
| Completed | 1 | 92 | RoW | Telitacicept, RC18, standard therapy | RemeGen Co., Ltd. | Systemic Lupus Erythematosus | 10/23 | 11/23 | | |
JY231、ADs, NCT06243159: JY231(Internal Clinical Drug Code) Injection for the Treatment of Refractory Autoimmune Diseases |
|
|
| Not yet recruiting | 1 | 20 | RoW | JY231, Fludarabine, Cyclophosphamide | Shanxi Bethune Hospital | Autoimmune Diseases | 12/26 | 12/26 | | |
NCT06400537: Clinical Study of A-319 in the Treatment of Active/Refractory Systemic Lupus Erythematosus |
|
|
| Recruiting | 1 | 18 | RoW | A-319 | Wuhan Union Hospital, China, ITabMed Co., Ltd. | Systemic Lupus Erythematosus | 05/25 | 05/26 | | |
NCT06056921: Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease |
|
|
| Recruiting | 1 | 24 | RoW | CD19 targeted CAR-T cells | Chongqing Precision Biotech Co., Ltd | SLE (Systemic Lupus), Sjogren's Syndrome, Systemic Scleroderma, Dermatomyositis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 12/25 | 08/26 | | |
| Recruiting | N/A | 116 | RoW | Leflunomide 10mg Tab, Prednisone Acetate, Placebos | Jiang lindi | Takayasu Arteritis | 12/22 | 12/22 | | |
| Cheng, Zhifeng |
EFFECT, NCT05902078: Eldecalcitol and Calcitriol in Postmenopausal Women With Low Bone Mineral Density or Mild Osteoporosis |
|
|
| Recruiting | 4 | 300 | RoW | Eldecalcitol capsules, Edirol, Calcitriol capsules, Haidewei | Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Chugai Pharma China Co., Ltd. | Low Bone Mineral Density, Postmenopausal Osteoporosis | 06/25 | 12/25 | | |
NCT04373967: Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 Diabetes |
|
|
| Recruiting | 3 | 424 | RoW | Victoza®., Metformin Hydrochloride, TQZ2451 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Type 2 Diabetes | 12/21 | 12/21 | | |
| Completed | 3 | 533 | RoW | Chiglitazar 32mg, Bilessglu, CS038, Chiglitazar 48mg, Placebo, Chiglitazar simulator, Metformin Hydrochloride, Glucophage | Chipscreen Biosciences, Ltd. | Type 2 Diabetes | 02/23 | 02/23 | | |
NCT05102149: Study to Evaluate the Safety and Efficacy of PB-201 in Treatment-naive Patients With Type 2 Diabetes Mellitus |
|
|
| Recruiting | 3 | 672 | RoW | PB-201, Vildagliptin, PB-201 matched placebo, Vildagliptin matched placebo | PegBio Co., Ltd. | Type 2 Diabetes Mellitus (T2DM) | 11/23 | 04/25 | | |
NCT06350890: Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes |
|
|
| Active, not recruiting | 3 | 408 | RoW | HTD1801, berberine ursodeoxycholate, Placebo | HighTide Biopharma Pty Ltd | T2DM (Type 2 Diabetes Mellitus) | 03/25 | 09/25 | | |
Symphony2, NCT06353347: Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Metformin |
|
|
| Active, not recruiting | 3 | 551 | RoW | HTD1801, berberine ursodeoxycholate, Placebo | HighTide Biopharma Pty Ltd | Type 2 Diabetes Mellitus | 03/25 | 12/25 | | |
ACHIEVE-2, NCT06192108: A Study of Orforglipron (LY3502970) Compared With Dapagliflozin in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin |
|
|
| Recruiting | 3 | 888 | Europe, US, RoW | Orforglipron, LY3502970, Dapagliflozin | Eli Lilly and Company | Type 2 Diabetes | 10/25 | 10/25 | | |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
QWINT-2, NCT05362058: A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time |
|
|
| Completed | 3 | 928 | Europe, Canada, Japan, US, RoW | Insulin Efsitora Alfa, LY3209590 and Basal Insulin-FC, Insulin Degludec | Eli Lilly and Company | Diabetes, Type 2 Diabetes | 04/24 | 04/24 | | |
NCT05352516 / 2022-002188-31: A Study to Evaluate the Efficacy and Safety of HLX14 vs. Denosumab Prolia® in Postmenopausal Women With Osteoporosis at High Risk of Fracture |
|
|
| Completed | 3 | 514 | RoW | HLX14, Prolia® | Shanghai Henlius Biotech, Shanghai Henlius Biotech, Inc. | Postmenopausal | 12/23 | 07/24 | | |
| Completed | 3 | 257 | RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Diabetes Type 2, Diabetes Mellitus, Glucose Metabolism Disorders, Metabolic Disease, Endocrine System Diseases | 07/24 | 07/24 | | |
ATTAIN-OSA, NCT06649045: A Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight |
|
|
| Recruiting | 3 | 600 | Europe, Japan, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | OSA, Overweight or Obesity | 11/26 | 01/27 | | |
ACHIEVE-1, NCT05971940: A Study of Orforglipron (LY3502970) in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone |
|
|
| Active, not recruiting | 3 | 520 | Japan, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | Type 2 Diabetes | 04/25 | 04/25 | | |
NCT05963022: A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes (SURPASS-CN-MONO) |
|
|
| Completed | 3 | 168 | RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Type 2 Diabetes | 10/24 | 10/24 | | |
ATTAIN-2, NCT05872620: A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes |
|
|
| Active, not recruiting | 3 | 1500 | Europe, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | Obesity, Overweight, Type 2 Diabetes | 08/25 | 08/25 | | |
ACHIEVE-3, NCT06045221: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin |
|
|
| Active, not recruiting | 3 | 1576 | Japan, US, RoW | Orforglipron, LY3502970, Semaglutide | Eli Lilly and Company | Type 2 Diabetes | 09/25 | 09/25 | | |
ATTAIN-1, NCT05869903: A Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities |
|
|
| Active, not recruiting | 3 | 3000 | Europe, Japan, US, RoW | Orforglipron, LY3502970, Placebo | Eli Lilly and Company | Obesity, Overweight, Overweight or Obesity | 07/25 | 07/27 | | |
TRIUMPH-4, NCT05931367: A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee |
|
|
| Active, not recruiting | 3 | 405 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Obesity, Overweight, Osteo Arthritis Knee | 02/26 | 03/26 | | |
| Active, not recruiting | 3 | 2300 | Europe, Canada, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Obesity, Overweight, Osteoarthritis, Knee, Obstructive Sleep Apnea | 04/26 | 05/26 | | |
TRIUMPH-2, NCT05929079: A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight |
|
|
| Active, not recruiting | 3 | 1000 | Europe, US, RoW | Retatrutide, LY3437943, Placebo | Eli Lilly and Company | Type 2 Diabetes, Obesity, Overweight, Obstructive Sleep Apnea | 05/26 | 05/26 | | |
| Active, not recruiting | 3 | 15374 | Europe, Canada, Japan, US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Obesity, Overweight | 10/27 | 10/27 | | |
KRAKEN, NCT05563246: A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events |
|
|
| Completed | 2 | 233 | Europe, Japan, US, RoW | LY3473329, Placebo | Eli Lilly and Company | Lipoprotein Disorder | 03/24 | 03/24 | | |
NCT06481085: To Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus |
|
|
| Not yet recruiting | 2 | 318 | RoW | HDM1002 50 mg, HDM1002, HDM1002 100 mg, HDM1002 200 mg, HDM1002 400 mg, HDM1002 200 mg BID, Placebo, Matching placebo for group A to group E | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Type 2 Diabetes | 04/25 | 04/25 | | |
NCT06118021: A Study of HS-20094 Evaluating Weight Loss in Obese and Overweight Chinese Subjects |
|
|
| Recruiting | 2 | 200 | RoW | HS-20094, HS-20094 injection, Placebo, Placebo injection | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Overweight and Obesity | 08/24 | 10/24 | | |
NCT06606483: A Study to Evaluate the Efficacy and Safety of MDR-001 in Subjects Who Are Obesity or Overweight |
|
|
| Not yet recruiting | 2 | 300 | RoW | MDR-001, Placebo | MindRank AI Ltd | Obesity, Overweight and Obesity | 07/25 | 09/25 | | |
NCT05593575: Efficacy and Safety of SPH3127 Tablets on Treating the Diabetic Kidney Disease |
|
|
| Recruiting | 2 | 320 | RoW | SPH3127+SPH3127matching placebo+valsartan matching placebo, SPH3127+valsartan matching placebo, SPH3127 matching placebo+valsartan | Shanghai Pharmaceuticals Holding Co., Ltd | Diabetic Kidney Disease | 06/25 | 06/25 | | |
| Active, not recruiting | 2 | 145 | Europe, Canada, Japan, US, RoW | GSK3858279, Placebo | GlaxoSmithKline | Pain | 10/24 | 01/25 | | |
NCT06606509: The Survey of Treatment and Metabolic Status of Type 1 Diabetes Mellitus (T1DM). |
|
|
| Not yet recruiting | N/A | 1000 | RoW | Continuous Glucose Monitoring System (GX-01S) | Nanjing First Hospital, Nanjing Medical University | Type1 Diabetes Mellitus | 10/26 | 06/27 | | |
NCT05866029: Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture |
|
|
| Recruiting | N/A | 2478 | RoW | Denosumab, Teriparatide | Peking Union Medical College Hospital | Osteoporotic Fractures | 09/26 | 09/26 | | |
| Huang, Huifang |
| Recruiting | N/A | 72 | RoW | | Fujian Medical University Union Hospital | AML, Adult | 10/24 | 06/25 | | |
| Hui, Huang F |
NCT05899725: The Efficacy and Safety of Corticosteroids in Combination With Ruxolitinib in the Management of Checkpoint Inhibitor Pneumonia |
|
|
| Recruiting | N/A | 60 | RoW | Corticosteroids, Corticosteroids and Ruxolitinib | Peking Union Medical College Hospital | Severe Checkpoint Inhibitor Pneumonitis | 03/25 | 06/25 | | |
| Gao, Fei |
EFFECT, NCT05902078: Eldecalcitol and Calcitriol in Postmenopausal Women With Low Bone Mineral Density or Mild Osteoporosis |
|
|
| Recruiting | 4 | 300 | RoW | Eldecalcitol capsules, Edirol, Calcitriol capsules, Haidewei | Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Chugai Pharma China Co., Ltd. | Low Bone Mineral Density, Postmenopausal Osteoporosis | 06/25 | 12/25 | | |
NCT04627363: HAIC Combined With Bevacizumab and Toripalimab for Advanced Hepatocellular Carcinama |
|
|
| Not yet recruiting | 2 | 30 | NA | Hepatic arterial infusion chemotherapy, Bevacizumab, Toripalimab | Sun Yat-sen University, Second Affiliated Hospital of Guangzhou Medical University | Hepatocellular Carcinoma, Bevacizumab, Liver Neoplasms, Toripalimab, Oxaliplatin | 06/22 | 06/23 | | |
C-couple, NCT04724226: Cryoablation Combined With Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | 2 | 34 | RoW | Camrelizumab; Apatinib, Cryoablation | Sun Yat-sen University | Hepatocellular Carcinoma | 08/23 | 08/24 | | |
T-Double, NCT04796025: TACE Combined With Sintilimab Plus Bevacizumab Biosimilar in Hepatocellular Carcinoma (BCLC-C Stage ): a Prospective Single-arm Phase II Clinical Study |
|
|
| Recruiting | 2 | 34 | RoW | Sintilimab; Bevacizumab Biosimilar, TACE | Sun Yat-sen University | Hepatocellular Carcinoma | 08/23 | 08/24 | | |
DoTH, NCT06646198: TIPS Plus Half-dose Donafenib in AHCC with PVTT-associated Portal Hypertension |
|
|
| Recruiting | 2 | 40 | RoW | Transjugular intrahepatic portosystemic shunt (TIPS), Donafenib | Fei Gao | Hepatocellular Carcinoma with PVTT | 05/26 | 12/26 | | |
| Not yet recruiting | 2 | 35 | RoW | Bevacizumab Biosimilar QL 1101, TACE | Sun Yat-sen University | Hepatocellular Carcinoma by BCLC Stage | 05/25 | 07/25 | | |
NCT05882370: TIPS Plus Cadonilimab in Advanced HCC with Tumor Thrombosis-associated Portal Hypertension:a Prospective, Single-arm, Phase II Study |
|
|
| Recruiting | 2 | 30 | RoW | Cadonilimab, transjugular intrahepatic portosystemic shunt (TIPS) | Fei Gao | Hepatocellular Carcinoma | 06/25 | 08/25 | | |
NCT04640116: TIPS Combined With Microwave Ablation in HCC Patients With Refractory Ascites |
|
|
| Not yet recruiting | N/A | 30 | NA | Transjugular intrahepatic portosystemic shunt (TIPS), microwave ablation (MWA) | Sun Yat-sen University, Second Affiliated Hospital of Guangzhou Medical University | Liver Diseases, Portal Hypertension, Cirrhosis, Liver, Ascites, Hepatocellular Carcinoma | 08/21 | 06/23 | | |
NCT05447403: Effect of Chewing Gum and WeChat Enhanced Instructions on the Bowel Preparation Quality in Patients With Constipation |
|
|
| Completed | N/A | 115 | RoW | Chewing gum combined with WeChat enhanced instructions | General Hospital of Shenyang Military Region | Colonoscopy, Colonic Polyp, Constipation | 08/23 | 08/23 | | |
NCT05866029: Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture |
|
|
| Recruiting | N/A | 2478 | RoW | Denosumab, Teriparatide | Peking Union Medical College Hospital | Osteoporotic Fractures | 09/26 | 09/26 | | |
| Contact, See Central |
| Active, not recruiting | 3 | 1600 | Europe, Canada, Japan, US, RoW | DS-8201a, Trastuzumab deruxtecan (T-DXd), T-DM1, Trastuzumab emtansine (T-DM1) | Daiichi Sankyo, AstraZeneca, NSABP Foundation Inc, German Breast Group, Spanish Breast Cancer Research Group (SOLTI) | HER2-Positive Primary Breast Cancer, Residual Invasive Breast Cancer | 12/25 | 12/30 | | |
|
|
| Completed | 2 | 342 | Japan | VN-0200 | Daiichi Sankyo | Respiratory Syncytial Virus Infections | 04/23 | 02/24 | | |
| Recruiting | 2 | 400 | Europe, Japan, US, RoW | HER3-DXd, Patritumab Deruxtecan, U3-1402 | Daiichi Sankyo, Merck Sharp & Dohme LLC | Advanced Solid Tumor, Melanoma, Head and Neck Cancer, Gastric Cancer, Ovarian Carcinoma, Cervical Cancer, Endometrial Cancer, Bladder Cancer, Esophageal Cancer, Pancreatic Carcinoma, Prostate Cancer | 06/25 | 04/26 | | |
NCT04703322: A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan |
|
|
| Active, not recruiting | 2 | 21 | Japan | Pexidartinib, TURALIO™, PLX3397 | Daiichi Sankyo Co., Ltd. | Tenosynovial Giant Cell Tumor | 03/23 | 05/26 | | |
| Recruiting | 1/2 | 250 | Japan, US | Ifinatamab deruxtecan (I-DXd) | Daiichi Sankyo, Merck Sharp & Dohme LLC | Advanced Solid Tumor, Malignant Solid Tumor | 12/25 | 03/27 | | |
|
KEYNOTE-D35, NCT05438420: Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 120 | US, RoW | Q702, Pembrolizumab, KEYTRUDA® | Qurient Co., Ltd., Merck Sharp & Dohme LLC | Esophageal Cancer, Gastric Cancer, Hepatocellular Cancer, Cervical Cancer | 10/25 | 06/26 | | |
| Recruiting | 1/2 | 130 | US, RoW | Q901, KEYTRUDA® (pembrolizumab) | Qurient Co., Ltd., Merck Sharp & Dohme LLC | Advanced Cancer, Metastatic Cancer | 12/25 | 08/26 | | |
| Recruiting | 1/2 | 430 | Europe, Japan, US | DS-3939a | Daiichi Sankyo | Advanced Solid Tumor, Metastatic Solid Tumor | 03/26 | 07/27 | | |
| Recruiting | 1 | 309 | Europe, Japan, US, RoW | HER3-DXd (FL-DP), U3-1402, HER3-DXd (CTM-1 Lyo-DP), HER3-DXd (CTM-3 Lyo-DP) | Daiichi Sankyo, Merck Sharp & Dohme LLC | Non-Small Cell Lung Cancer (NSCLC) | 03/26 | 12/26 | | |
|
|
NCT04648254: Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumor |
|
|
| Active, not recruiting | 1 | 78 | US | Q702 | Qurient Co., Ltd. | Solid Tumor, Advanced Cancer, Metastatic Cancer | 12/24 | 02/25 | | |
TROPION-Lung02, NCT04526691: Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer |
|
|
| Active, not recruiting | 1 | 145 | Europe, Japan, US, RoW | Datopotamab deruxtecan, Dato-DXd, KEYTRUDA®, pembrolizumab, Carboplatin, Cisplatin | Daiichi Sankyo, Merck Sharp & Dohme LLC | Advanced or Metastatic NSCLC | 06/25 | 06/25 | | |
|
|
